HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hormone therapy and thromboembolic disease.

AbstractPURPOSE OF REVIEW:
Hormone therapy increases the risk of venous thromboembolism (VTE). To reduce this risk, changes in dosage, composition and route of administration have been made over the years. This review provides a summary of the available evidence and an update on the most recent findings on the issue.
RECENT FINDINGS:
Contraceptives containing third-generation progestagens confer a higher risk of VTE than second-generation compounds. Little data are available on preparations containing less than 30 micarog of estrogen, new progestagens or levonorgestrel-releasing intrauterine devices. Hormone replacement therapy increases the risk of VTE by 2 to 3-fold. Transdermal administration may be less thrombogenic than oral administration, while different estrogens and progestagens may carry a different risk. VTE risk is further increased in carriers of inherited thrombophilia. Despite a similar increase in relative risk of thrombosis associated with hormone therapy, absolute risk is lower in fertile women and higher in postmenopausal ones. Universal screening for thrombophilia before prescribing hormone replacement therapy might be cost-effective.
SUMMARY:
Careful evaluation of individual risk factor is warranted before prescribing hormone therapy. Further investigations are needed to establish whether or not newer compounds are safer than older ones with respect to the risk of thrombosis.
AuthorsTullia Battaglioli, Ida Martinelli
JournalCurrent opinion in hematology (Curr Opin Hematol) Vol. 14 Issue 5 Pg. 488-93 (Sep 2007) ISSN: 1065-6251 [Print] United States
PMID17934355 (Publication Type: Journal Article, Review)
Chemical References
  • Estrogens
  • Progestins
Topics
  • Drug-Related Side Effects and Adverse Reactions
  • Estrogen Replacement Therapy (adverse effects)
  • Estrogens (adverse effects, therapeutic use)
  • Female
  • Humans
  • Postmenopause (drug effects)
  • Progestins (adverse effects, therapeutic use)
  • Risk Factors
  • Thromboembolism (chemically induced)
  • Thrombophilia (diagnosis)
  • Venous Thrombosis (chemically induced)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: